Company intelligence / Profile preview

Gusto

Morrisville, North Carolina, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Gusto Global’s live bacterial consortia (GUT-103 and GUT-108) demonstrated robust prevention and treatment of immune-mediated colitis in humanized mouse models, suggesting strong preclinical efficacy and mechanistic restoration of intestinal homeostasis. Both consortia reduced harmful bacteria and promoted healing metabolites; GUT-108 is expected to proceed to Phase 1 trials.

Therapeutic areas: OncologyGastroenterology
Modalities: Live biotherapeutic product therapyMicrobial therapy
Industry: Biotech

Partnerships

UNC-Chapel Hill (academic research and validation partner)

Beyond the preview

Go deeper on Gusto.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gusto.

Explore the full profile